• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 460263 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1419102687 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1419102687 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of Ariad Pharmaceuticals Under Pressure, Down 1.6%

Published on Fri, 03/15/2013 - 10:37
By Peter Chu

One of today's notable stocks in decline is Ariad Pharmaceuticals (NASDAQ:ARIA), down 1.6% to $21.84. The Dow Jones Industrial Average is now trading 0.3% lower to 14,494 and the S&P is trading 0.2% lower to 1,559.

ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.

In the past 52 weeks, shares of Ariad Pharmaceuticals have traded between a low of $14.10 and a high of $25.40 and are now at $21.84, which is 55% above that low price. The 200-day and 50-day moving averages have moved 0.52% higher and 0.98% higher over the past week, respectively.

There is potential upside of 29.1% for shares of Ariad Pharmaceuticals based on a current price of $21.84 and an average consensus analyst price target of $28.19. The stock should discover initial support at its 50-day moving average (MA) of $20.42 and subsequent support at its 200-day MA of $20.39.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Earnings Look Back: Genesco Is Up 5.1% S...

When Genesco (NYSE:GCO) reported earnings two weeks ago on December 5th, 2014, analysts ...

Post Earnings Update: Vail Resorts Has C...

12 days ago, on December 8th, 2014, Vail Resorts (NYSE:MTN) reported its earnings. Ana ...

Cantel Medical Earnings Review: 10 Days ...

10 days ago, on December 10th, 2014, Cantel Medical (NYSE:CMN) reported its earnings. ...

ABM Industries Earnings Review: 12 Days ...

12 days ago, on December 8th, 2014, ABM Industries (NYSE:ABM) reported its earnings. A ...

Post Earnings Update: Gildan Activewear ...

Two weeks ago on December 4th, 2014 Gildan Activewear (NYSE:GIL) reported earnings and ...

Earnings Look Back: Christopher & Banks ...

When Christopher & Banks (NYSE:CBK) reported earnings two weeks ago on December 4th, 20 ...

Post Earnings Update: Methode Electronic...

9 days ago, on December 11th, 2014, Methode Electronics (NYSE:MEI) reported its earning ...

Phillips-Van Heusen Earnings In Retrospe...

Two weeks ago on December 3rd, 2014 Phillips-Van Heusen (NYSE:PVH) reported earnings an ...